Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma

被引:388
作者
Hiraoka, K
Miyamoto, M
Cho, Y
Suzuoki, M
Oshikiri, T
Nakakubo, Y
Itoh, T
Ohbuchi, T
Kondo, S
Katoh, H
机构
[1] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA
[2] Hokkaido Univ, Grad Sch Med, Div Canc Med, Kita Ku, Sapporo, Hokkaido 0608638, Japan
[3] Hokkaido Univ Hosp, Dept Surg Pathol, Kita Ku, Sapporo, Hokkaido 0608638, Japan
[4] Minami Ichijo Hosp, Dept Thorac Surg, Chuo Ku, Sapporo, Hokkaido 0600061, Japan
基金
日本学术振兴会;
关键词
non-small-cell lung carcinoma; prognostic factor; CD8(+) T cells; CD4(+) T cells; immunohistochemistry;
D O I
10.1038/sj.bjc.6602934
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The purpose of this study was to clarify the relationship between the number of tumour-infiltrating T lymphocytes and the clinicopathological features and clinical outcome in patients with non-small-cell lung cancer (NSCLC). Tissue specimens from 109 patients who underwent surgical resection for NSCLC were immunohistochemically analysed for CD4 and CD8 expression. Patients were classified into two groups according to whether their tumours exhibited a 'high' or 'low' level of CD8(+) or CD4(+) lymphocyte infiltration. Although the level of infiltration by CD8(+) T cells alone had no prognostic significance, the survival rate for patients with both 'high' CD8(+) and 'high' CD4(+) T-cell infiltration was significantly higher than that for the other groups (log-rank test, P = 0.006). Multivariate analysis indicated that concomitant high CD8(+) and high CD4(+) T-cell infiltration was an independent favourable prognostic factor ( P = 0.0092). In conclusion, the presence of high levels of both CD8(+) T cells and CD4(+) T cells is a significant indicator of a better prognosis for patients with NSCLC, and cooperation between these cell populations may allow a significantly more potent antitumour response than either population alone.
引用
收藏
页码:275 / 280
页数:6
相关论文
共 39 条
[1]  
ALBERTI W, 1995, BRIT MED J, V311, P899
[2]   Induction of tumor-specific T cell response by cognating tumor cells with foreign antigen-primed Th cells [J].
Cheng, TY ;
Wu, JT ;
Lin, RH .
INTERNATIONAL IMMUNOLOGY, 1998, 10 (10) :1397-1406
[3]  
Cho Y, 2003, CANCER RES, V63, P1555
[4]  
FIORENTINO DF, 1991, J IMMUNOL, V147, P3815
[5]  
FIORENTINO DF, 1991, J IMMUNOL, V146, P3444
[6]   CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma [J].
Fukunaga, A ;
Miyamoto, M ;
Cho, Y ;
Murakami, S ;
Kawarada, Y ;
Oshikiri, T ;
Kato, K ;
Kurokawa, T ;
Suzuoki, M ;
Nakakubo, Y ;
Hiraoka, K ;
Itoh, T ;
Morikawa, T ;
Okushiba, S ;
Kondo, S ;
Katoh, H .
PANCREAS, 2004, 28 (01) :E26-E31
[7]   HISTOCOMPATIBILITY ANTIGENS ON MURINE TUMORS [J].
GOODENOW, RS ;
VOGEL, JM ;
LINSK, RL .
SCIENCE, 1985, 230 (4727) :777-783
[8]  
GREENBERG PD, 1991, ADV IMMUNOL, V49, P281
[9]   Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape [J].
Hahne, M ;
Rimoldi, D ;
Schroter, M ;
Romero, P ;
Schreier, M ;
French, LE ;
Schneider, P ;
Bornand, T ;
Fontana, A ;
Lienard, D ;
Cerottini, JC ;
Tschopp, J .
SCIENCE, 1996, 274 (5291) :1363-1366
[10]   The central role of CD4+ T cells in the antitumor immune response [J].
Hung, K ;
Hayashi, R ;
Lafond-Walker, A ;
Lowenstein, C ;
Pardoll, D ;
Levitsky, H .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (12) :2357-2368